Giovanni Mauri1, Nicolò Gennaro2, Stefano De Beni3, Tiziana Ierace4, S Nahum Goldberg5,6, Marcello Rodari7, Luigi Alessandro Solbiati4,8. 1. Department of Interventional Radiology, IEO, European Institute of Oncology IRCCS, via Ripamonti 435, Milan, Italy. giovanni.mauri@ieo.it. 2. Training School in Radiology, Humanitas University, Pieve Emanuele, Milan, Italy. 3. Esaote S.p.A, Genoa, Italy. 4. Department of Radiology, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy. 5. Department of Radiology, Hadassah Hebrew University Medical Centre, Jerusalem, Israel. 6. Department of Radiology, Beth Israel Deaconess Medical Center, Boston, MA, USA. 7. Department of Nuclear Medicine, IRCCS Humanitas Clinical and Research Hospital, Rozzano, Milan, Italy. 8. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Abstract
PURPOSE: To assess the feasibility of US-18FDG-PET/CT fusion-guided microwave ablation of liver metastases either poorly visible or totally undetectable with US, CEUS and CT, but visualized by PET imaging. MATERIALS AND METHODS: Twenty-three patients with 58 liver metastases underwent microwave ablation guided by image fusion system that combines US with 18FDG-PET/CT images. In 28/58 tumors, 18FDG-PET/CT with contrast medium (PET/CECT) was used. The registration technical feasibility, registration time, rates of correct targeting, technical success at 24 h, final result at 1 year and complications were analyzed and compared between the PET/CT and PET/CECT groups. RESULTS: Registration was successfully performed in all cases with a mean time of 7.8 + 1.7 min (mean + standard deviation), (4.6 + 1.5 min for PET/CECT group versus 10.9 + 1.8 min for PET/CT group, P < 0.01). In total, 46/58 (79.3%) tumors were correctly targeted, while 3/28 (10.7%) and 9/30 (30%) were incorrectly targeted in PET/CT and PET/CECT group, respectively (P < 0.05). Complete ablation was obtained at 24 h in 70.0% of cases (n = 40 tumors), 23/28 (82.1%) in the PET/CECT group and 17/30 (56.7%) in the PET/CT group (P < 0.037). Fourteen tumors underwent local retreatment (11 ablations, 2 with resection and 1 with stereotactic body radiation therapy), while 4 tumors could not be retreated because of distant disease progression and underwent systemic therapy. Finally, 54/58 (93.1%) tumors were completely treated at 1 year. One major complication occurred, a gastrointestinal hemorrhage which required surgical repair. CONCLUSIONS: Percutaneous ablation of 18FDG-PET-positive liver metastases using fusion imaging of real-time US and pre-acquired 18FDG-PET/CT images is feasible, safe and effective. Contrast-enhanced PET/CT improves overall ablation accuracy and shortens procedural duration time.
PURPOSE: To assess the feasibility of US-18FDG-PET/CT fusion-guided microwave ablation of liver metastases either poorly visible or totally undetectable with US, CEUS and CT, but visualized by PET imaging. MATERIALS AND METHODS: Twenty-three patients with 58 liver metastases underwent microwave ablation guided by image fusion system that combines US with 18FDG-PET/CT images. In 28/58 tumors, 18FDG-PET/CT with contrast medium (PET/CECT) was used. The registration technical feasibility, registration time, rates of correct targeting, technical success at 24 h, final result at 1 year and complications were analyzed and compared between the PET/CT and PET/CECT groups. RESULTS: Registration was successfully performed in all cases with a mean time of 7.8 + 1.7 min (mean + standard deviation), (4.6 + 1.5 min for PET/CECT group versus 10.9 + 1.8 min for PET/CT group, P < 0.01). In total, 46/58 (79.3%) tumors were correctly targeted, while 3/28 (10.7%) and 9/30 (30%) were incorrectly targeted in PET/CT and PET/CECT group, respectively (P < 0.05). Complete ablation was obtained at 24 h in 70.0% of cases (n = 40 tumors), 23/28 (82.1%) in the PET/CECT group and 17/30 (56.7%) in the PET/CT group (P < 0.037). Fourteen tumors underwent local retreatment (11 ablations, 2 with resection and 1 with stereotactic body radiation therapy), while 4 tumors could not be retreated because of distant disease progression and underwent systemic therapy. Finally, 54/58 (93.1%) tumors were completely treated at 1 year. One major complication occurred, a gastrointestinal hemorrhage which required surgical repair. CONCLUSIONS: Percutaneous ablation of 18FDG-PET-positive liver metastases using fusion imaging of real-time US and pre-acquired 18FDG-PET/CT images is feasible, safe and effective. Contrast-enhanced PET/CT improves overall ablation accuracy and shortens procedural duration time.
Authors: Lorenzo Monfardini; Nicolò Gennaro; Franco Orsi; Paolo Della Vigna; Guido Bonomo; Gianluca Varano; Luigi Solbiati; Giovanni Mauri Journal: Eur Radiol Date: 2021-04-19 Impact factor: 5.315
Authors: Marco Calandri; Valeria Ruggeri; Patrizia Carucci; Stefano Mirabella; Andrea Veltri; Paolo Fonio; Carlo Gazzera Journal: Radiol Med Date: 2019-07-03 Impact factor: 3.469
Authors: Nikiforos Vasiniotis Kamarinos; Efsevia Vakiani; Sho Fujisawa; Mithat Gonen; Ning Fan; Yevgeniy Romin; Richard K G Do; Etay Ziv; Joseph P Erinjeri; Elena N Petre; Vlasios S Sotirchos; Juan C Camacho; Stephen B Solomon; Katia Manova-Todorova; Constantinos T Sofocleous Journal: J Vasc Interv Radiol Date: 2021-11-17 Impact factor: 3.682
Authors: T R F van Steenbergen; M Smits; T W J Scheenen; I M van Oort; J Nagarajah; M M Rovers; N Mehra; J J Fütterer Journal: Cardiovasc Intervent Radiol Date: 2019-08-23 Impact factor: 2.740